Skip Navigation


JAC Advance Access originally published online on June 2, 2005
Journal of Antimicrobial Chemotherapy 2005 56(1):247-249; doi:10.1093/jac/dki179
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/1/247    most recent
dki179v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Husson, M. O.
Right arrow Articles by Wallaert, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Husson, M. O.
Right arrow Articles by Wallaert, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis

M. O. Husson1,*, N. Wizla-Derambure2, D. Turck1, P. Gosset3 and B. Wallaert3

1 EA 3925, Laboratoire de Bactériologie-Hygiène, Hôpital Calmette, Boulevard du Professeur J. Leclercq, 59037 Lille, France; 2 Centre de Ressources et de Compétences pour la Mucoviscidose, Clinique de Pédiatrie, Hôpital Jeanne de Flandre, 59037 Lille, France; 3 Centre de Ressources et de Compétences pour la Mucoviscidose Adultes, Hôpital Calmette, and Inserm U416, Institut Pasteur de Lille, 59800 Lille, France

Received 2 February 2005; returned 22 February 2005; revised 15 March 2005; accepted 28 April 2005

* Corresponding author. Tel: +33-320-44-49-44; Fax: +33-320-44-48-95; E-mail: mohusson{at}chru-lille.fr

Objectives: The aim of this study was to evaluate the anti-inflammatory properties of intermittent inhaled tobramycin.

Methods: To establish this, we initiated a prospective study to measure the concentration of the three pro-inflammatory cytokines IL-8, IL-6 and TNF-{alpha} in the sputum from 20 cystic fibrosis (CF) patients (15 teenagers and 5 young adults) during cycles and off cycles.

Results: A significant decrease in IL-8 (P = 0.001) and a more moderate decrease in IL-6 (P = 0.046) and TNF-{alpha} (P = 0.052) levels were observed during cycles, even if no significant decrease in the number of leucocytes was observed.

Conclusions: These results associated with a decrease in the Pseudomonas aeruginosa population can contribute in part to the beneficial effect of intermittent inhaled tobramycin on pulmonary function.

Keywords: Pseudomonas aeruginosa , IL-8 , IL-6 , TNF-{alpha}


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
H. Mussaffi, E. M. Fireman, M. Mei-Zahav, D. Prais, and H. Blau
Induced Sputum in the Very Young: A New Key to Infection and Inflammation
Chest, January 1, 2008; 133(1): 176 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. D. Sagel, J. F. Chmiel, and M. W. Konstan
Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease
Proceedings of the ATS, August 1, 2007; 4(4): 406 - 417.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.